Circulating contact-pathway-activating microparticles together with factors IXa and XIa induce spontaneous clotting in plasma of hematology and cardiologic patients

PLoS One. 2014 Jan 31;9(1):e87692. doi: 10.1371/journal.pone.0087692. eCollection 2014.

Abstract

Background and objective: Using an in vitro experimental model of immobilized tissue factor-initiated clot growth in platelet-free plasma (thrombodynamics), we observed formation of activator-independent isolated spontaneous clots (SC) throughout the plasma volume in patients with cardiac infarction, acute leukemia, hemolytic anemia, and some other disorders. The aim of this work was to characterize this phenomenon and to identify the mechanisms of SC formation.

Methods and results: Tissue factor inhibitor (VIIai) prevented SC in only 2 out of 23 patient plasma samples. Specific inhibitors of factors IXa and XIa were efficient in all 8 cases that we tested. Also, only factors IXa and XIa added to normal donors' plasma induced SC formations from isolated centers, in a pattern similar to that in patients' plasma. In contrast, factors VIIa, Va, tissue factor induced uniform plasma clotting. SC disappeared after high-speed centrifugation. However, phospholipid supplementation of centrifuged plasma returned them at least partially in 5 out of 22 patients' plasmas, indicating some other role of microparticles than providing phospholipid surface. Circulating procoagulant microparticles isolated from plasma directly activated factor XII in buffer and in diluted plasma. Flow cytometry revealed an increase in procoagulant microparticles in patients' plasmas with SC.

Conclusion: Our data suggest that combination of circulating active factors (specifically, factors IXa and XIa) with circulating procoagulant and contact-pathway-activating microparticles is the predominant mechanism causing spontaneous clotting in patient plasma.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Anemia, Hemolytic / blood*
  • Anemia, Hemolytic / pathology
  • Blood Coagulation*
  • Cell-Derived Microparticles / metabolism*
  • Cell-Derived Microparticles / pathology
  • Factor IXa / metabolism*
  • Factor XIa / metabolism*
  • Female
  • Humans
  • Leukemia / blood*
  • Leukemia / pathology
  • Male
  • Myocardial Infarction / blood*
  • Myocardial Infarction / pathology

Substances

  • Factor IXa
  • Factor XIa

Grants and funding

The study was partially supported by HemaCore LLC, by the Russian Foundation for Basic Research grants 11-04-00303, 11-04-12080, 12-04-00438, 12-04-33055, and by the Russian Academy of Sciences Presidium Basic Research Programs 'Molecular and Cellular Biology', 'Basic Science for Medicine', 'Integrative Physiology', and 'Molecular Mechanisms of Physiologic Functions'. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.